1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
P/E ratio for 180 Life Sciences Corp. (ATNF)
P/E ratio as of 2023: -0.08
According to 180 Life Sciences Corp.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.08. At the end of 2022 the company had a P/E ratio of -0.17.
P/E ratio history for 180 Life Sciences Corp. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.08 |
| 2022 | -0.17 |
| 2021 | -5.98 |
| 2020 | -4.06 |
| 2019 | -0.67 |
| 2018 | -1.02 |
| 2017 | 89.04 |